Overall Revenue and Profit Growth
CSL Group revenue grew by 5% on a constant currency basis. NPATA increased by 14% and NPAT grew by 17%.
Dividend Increase
Final dividend increased by 12% to USD 1.62 per share.
Free Cash Flow Improvement
Free cash flow increased by 58%.
Plasma Yield Improvements
Yield improvements are ahead of plan, leading to increased efficiency in plasma collection.
Demerger of CSL Seqirus
Announced intent to demerge CSL Seqirus as an independent ASX-listed entity by fiscal year 2026.
Share Buyback Program
Introduction of a multiyear share buyback program starting with AUD 750 million in FY '26.
Strong Market Leadership in Hemophilia
CSL's hemophilia franchise demonstrated market leadership with growth of 13% at constant currency.